GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ('Invizius'), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.

2023年10月24日，苏格兰格拉斯哥/PRNewswire/-Invizius Limited（'Invizius'），一家为透析患者开发突破性治疗的生物技术公司，很高兴地宣布任命Bernard Canaud教授到其临床咨询委员会。

Professor Canaud is a leading authority on kidney disease and dialysis. He has over 40 years of experience in the field, has published more than 350 peer-reviewed articles on the subject, and in 2009 was awarded the Legion d'Honneur – the highest French order of merit – for his medical achievements.

Canaud教授是肾脏疾病和透析的主要权威。他在该领域拥有40多年的经验，已发表了350多篇有关该主题的同行评审文章，并于2009年因其医疗成就而被授予法国最高优异奖d'Honneur军团。

He is currently Emeritus Professor of Nephrology at the Montpellier University School of Medicine in France and previously headed the Nephrology, Dialysis and Intensive Care Department at Lapeyronie University Hospital in Montpellier. He served as Chief Medical Officer for Fresenius Medical Care's Europe, Middle East, Africa and Latin America division from 2012 to 2018, and as its global Chief Medical Scientist from 2019 to 2021.

他目前是法国蒙彼利埃大学医学院肾脏病学名誉教授，此前曾担任蒙彼利埃Lapeyronie大学医院肾脏病，透析和重症监护科主任。他于2012年至2018年担任Fresenius Medical Care的欧洲，中东，非洲和拉丁美洲分部的首席医疗官，并于2019年至2021年担任其全球首席医学科学家。

He has served on the editorial boards of many nephrology journals and is a member of the European Dialysis and Transplant Association (EDTA), the American Society of Nephrology (ASN), the International Society of Nephrology (ISN) and the French Society of Nephrology. He is also a past president of the Société Francophone de Dialyse (SFD)..

他曾在许多肾脏病学期刊的编辑委员会任职，并且是欧洲透析和移植协会（EDTA），美国肾脏病学会（ASN），国际肾脏病学会（ISN）和法国肾脏病学会的成员。他还是SociétéFrancophonede Dialyse（SFD）的前任总裁。。

Invizius is developing its novel, complement regulation biotechnology into breakthrough treatments for patients on dialysis, to improve the poor patient outcomes that have persisted for decades. Its lead product, H-Guard®, is for Haemodialysis and is designed to preserve renal function and cardiovascular health and improve patients' Quality of Life.

Invizius正在开发其新颖的补体调节生物技术，为透析患者提供突破性治疗，以改善持续数十年的不良患者预后。其主要产品H-Guard®用于血液透析，旨在保护肾功能和心血管健康，改善患者的生活质量。

By taking a precision medicine approach, treatment will target patients at highest risk of life-threatening complications..

通过采取精准医学方法，治疗将针对危及生命的并发症风险最高的患者。。

Richard Boyd, Chief Executive Officer of Invizius, said: 'We are delighted and honored to have Professor Canaud join Invizius at an important time of growth and development for the company. We are now beginning the First-in-Human study of H-Guard following recent approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Invizius首席执行官Richard Boyd说：“我们很高兴并很荣幸让Canaud教授在公司成长和发展的重要时刻加入Invizius。在英国药品和保健品监管机构（MHRA）最近批准后，我们现在开始对H-Guard进行首次人体研究。

Professor Canaud's unrivalled experience in the field of nephrology will be instrumental as we look to transform the treatment landscape for dialysis patients.'.

Canaud教授在肾脏病学领域无与伦比的经验将有助于我们改变透析患者的治疗方案。

Professor Bernard Canaud, commented: 'Invizius' unique product H-Guard has the potential to reduce the therapeutic burden and save patients' lives by addressing the inappropriate activation of the complement system. In spite of significant advances in the field of biocompatibility, studies have demonstrated that the persistent activation of the complement system by extracorporeal blood purification or nanomedicine therapy remains potentially harmful in the long and short term for patients exposed to these therapies.

Bernard Canaud教授评论说：“Invizius”独特的产品H-Guard有可能通过解决补体系统的不适当激活来减轻治疗负担并挽救患者的生命。尽管在生物相容性领域取得了重大进展，但研究表明，通过体外血液净化或纳米医学疗法持续激活补体系统对于暴露于这些疗法的患者在长期和短期内仍然具有潜在危害。

By targeting factor H and inhibiting both the alternate complement activation pathway and its amplification loop with H-Guard, we have the ability and potential to make a tremendous difference to patients while mitigating associated risks.'.

通过靶向因子H并用H-Guard抑制替代补体激活途径及其扩增环，我们有能力和潜力在减轻相关风险的同时对患者产生巨大影响。

Invizius will be attending the upcoming American Society of Nephrology (ASN) Kidney Week 2023 at the Pennsylvania Convention Center in Philadelphia, PA, on 2 to 5 November. Do get in contact if you would like to set up a meeting or require further information.

Invizius将于11月2日至5日在宾夕法尼亚州费城宾夕法尼亚公约中心参加即将到来的美国肾脏病学会（ASN）肾脏周2023。如果您想建立会议或需要更多信息，请联系。

About Invizius

关于Invizius

Invizius is developing a portfolio of second generation complement therapies to address a range of autoimmune and inflammatory diseases. Invizius' proprietary approach was born out of over ten years of research by Dr Andy Herbert into how pathogenic microbes evade the human complement system. The novel mechanism of action enhances the activity of the body's own complement regulators to effectively downregulate immune responses while maintaining antimicrobial protection.

Invizius正在开发一系列第二代补体疗法，以解决一系列自身免疫性和炎症性疾病。Invizius的专有方法诞生于Andy Herbert博士十多年来对致病微生物如何逃避人类补体系统的研究。新的作用机制增强了身体自身补体调节剂的活性，有效地下调免疫反应，同时保持抗菌保护。

The lead product, H-Guard, addresses serious complement-driven complications of haemodialysis, and enables additional indications in other extra-corporeal treatments (ECMO, cardiopulmonary bypass). A second product is being developed to extend the period that patients can sustain home-based, peritoneal dialysis..

主要产品H-Guard解决了严重的补体驱动的血液透析并发症，并为其他体外治疗（ECMO，体外循环）提供了额外的适应症。正在开发第二种产品，以延长患者可以维持家庭腹膜透析的时间。。

The company is working with Key Opinion Leaders from University of Manchester NHS Trust, Karolinska Institutet, University of Heidelberg, University Medical Centre Groningen, University of Oxford, and University of Strathclyde. It is backed by Mercia, Downing, Calculus, and Solvay, a corporate VC. Other investors include Edinburgh University's Old College Capital fund, Scottish Enterprise, and well-known life science investor, Dr Jonathan Milner..

该公司正在与曼彻斯特大学NHS信托基金，卡罗林斯卡研究所，海德堡大学，格罗宁根大学医学中心，牛津大学和斯特拉斯克莱德大学的主要意见领袖合作。它得到了Mercia，Downing，Calculus和公司VC Solvay的支持。其他投资者包括爱丁堡大学的老学院资本基金，苏格兰企业以及着名的生命科学投资者Jonathan Milner博士。。

For more information on Invizius, please visit: www.invizius.com

有关Invizius的更多信息，请访问：www.Invizius.com

SOURCE Invizius

来源Invizius